Purpose: The purpose of this study is to review studies of using low-dose radiation as a treatment for the inflammation of the tissue and pneumonia resulting from COVID-19. These studies were compared with the risk of developing lung cancer during performed dose for the treatment of COVID-19 in radiation therapy.
Methods: Our study focused on in vitro, in vivo, and clinical reports of using low dose radiation for the treatment of inflammation, pneumonia, and COVID-19. The risk of lung cancer resulting from the suggested dose in these studies was also evaluated.
Results: Studies showed that the use of low doses up to 1.5 Gy eliminates tissue inflammation and pneumonia by stimulating macrophages in different line cells, animals, and human, also suggested doses for low dose radiation therapy do not remarkably increase the lung cancer risk.
Conclusion: Low-dose has been effective in treating inflammation and pneumonia caused by COVID-19 in humans up to 80%. Since suggested doses do not remarkably increase the lung cancer risk, low-dose radiation can be an adjuvant treatment for COVID-19 patients. Since no definitive treatment has been found for COVID-19, it is recommended for patients with COVID-19 whose condition is deteriorating.
Funding Support, Disclosures, and Conflict of Interest: There is no funding. There is no conflict of interest.
Not Applicable / None Entered.